Open-house original-medicine discount agreements for cobimetinib

Summary

The tender concerns open-house discount agreements for the medicine containing the active substance cobimetinib. The participating health insurance funds intend to conclude agreements with all suitable pharmaceutical companies under uniform, non-negotiable conditions. No exclusivity is guaranteed to individual contracting partners. Participation is possible at any time during the contract period. The contract may last up to 24 months from 1 November 2026 and ends no later than 31 October 2028, or earlier if the patent or market exclusivity expires. Further participation and contract requirements must be checked in the official tender documents.